{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:56:02Z","timestamp":1790290562669,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.clon.2007.05.006","type":"journal-article","created":{"date-parts":[[2007,7,11]],"date-time":"2007-07-11T07:27:44Z","timestamp":1184138864000},"page":"572-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Experience of the Use of Trabectedin (ET-743, Yondelis\u2122) in 21 Patients with Pre-treated Advanced Sarcoma from a Single Centre"],"prefix":"10.1016","volume":"19","author":[{"given":"R.","family":"Roylance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"McTiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.clon.2007.05.006_bib1","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"issue":"14","key":"10.1016\/j.clon.2007.05.006_bib2","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1021\/jm990241l","article-title":"Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove","volume":"42","author":"Zewail-Foote","year":"1999","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.clon.2007.05.006_bib3","first-page":"179","article-title":"Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA","volume":"14","author":"Bonfanti","year":"1999","journal-title":"Anticancer Drug Des"},{"issue":"8","key":"10.1016\/j.clon.2007.05.006_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative\u00a0activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clon.2007.05.006_bib5","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2001.19.5.1256","article-title":"Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors","volume":"19","author":"Taamma","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2007.05.006_bib6","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2001.19.5.1248","article-title":"Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients\u2013preliminary evidence of activity","volume":"19","author":"Delaloge","year":"2001","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2007.05.006_bib7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00001813-200204000-00007","article-title":"Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study","volume":"13","author":"van Kesteren","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.clon.2007.05.006_bib8","first-page":"75","article-title":"A phase I and pharmacokinetic study of ecteinascidin-743 on a daily \u00d7 5 schedule in patients with solid malignancies","volume":"8","author":"Villalona-Calero","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clon.2007.05.006_bib9","first-page":"231","article-title":"Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies","volume":"7","author":"Ryan","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.clon.2007.05.006_bib10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2007.05.006_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2007.05.006_bib12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","article-title":"Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial","volume":"23","author":"Le Cesne","year":"2005","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clon.2007.05.006_bib13","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2007.05.006_bib14","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.11563","article-title":"Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma","volume":"98","author":"Laverdiere","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clon.2007.05.006_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0959-8049(01)00398-7","article-title":"Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas","volume":"38","author":"Van Glabbeke","year":"2002","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.clon.2007.05.006_bib16","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2000.18.14.2676","volume":"18","author":"Le Cesne","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2007.05.006_bib17","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1200\/jco.2004.22.90140.9000","article-title":"Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy","volume":"22","author":"Samuels","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2007.05.006_bib18","first-page":"187a","article-title":"Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743","volume":"19","author":"Gomez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655507006462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655507006462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:32:05Z","timestamp":1760542325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655507006462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0936655507006462"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2007.05.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience of the Use of Trabectedin (ET-743, Yondelis\u2122) in 21 Patients with Pre-treated Advanced Sarcoma from a Single Centre","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2007.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}